ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 22.9 | 26.9 | 23.7 |
| Other income | 0.6 | 1.3 | 0.8 |
| Total income | 23.5 | 28.2 | 24.6 |
| Profit before exceptional items & tax | 1.7 | 0.2 | 1.7 |
| Profit before tax | 1.7 | 0.2 | 1.7 |
| Net profit | 1.5 | 0.3 | 1.3 |
| Operating margin | 7.2% | 0.7% | 6.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +15.40% |
|---|---|
| Net profit, quarter on quarter | +400.00% |
| Revenue, year on year | -3.40% |
| Operating profit, year on year | +22.20% |
| Operating profit, quarter on quarter | +200.00% |
NSE results filing, NSE: VAISHALI. Figures extracted from the filing.
Vaishali Pharma Ltd: key numbers
- Share price
- ₹6.99
- Market cap
- ₹94.36 Cr
- Revenue (annual)
- ₹108.8 Cr
- Net profit (annual)
- ₹4.16 Cr
- P/E (TTM)
- 21.3×Sector 43.8×
- Promoter holding
- 31.61%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaishali Pharma Ltd
All →Vaishali Pharma Management Change
Vaishali Pharma appointed Rohil Desai and Ketur Shah as independent directors, subject to shareholder approval. The board deferred a preferential issue proposal without any decision.
Vaishali Pharma Board Meeting Date
Vaishali Pharma has scheduled an audit committee meeting for 5 November 2026. Proposed agenda includes a fund raise via preferential issue and an increase in authorised capital.
Vaishali Pharma Preferential Issue
NSE has approved the listing of 45,37,865 equity shares allotted on a preferential basis by Vaishali Pharma Ltd, effective from October 16, 2026.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.
Vaishali Pharma Capital Structure Change
Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.